Piperacillin Sodium and Tazobactam Sodium for Injection

Piperacillin is a semi-synthetic penicillin antibiotic, and tazobactam is a beta-lactamase inhibitor. This product has antibacterial effects on piperacillin-sensitive bacteria and the following bacteria that produce beta-lactamase and are resistant to piperacillin: Gram-negative bacteria: most plasmid-mediated beta-lactamase-producing and non-producing bacteria: Escherichia coli, Klebsiella (Klebsiella oxytoca, Klebsiella pneumoniae), Proteus (Proteus mirabilis, Proteus vulgaris), Salmonella, Shigella, Neisseria gonorrhoeae, Neisseria meningitidis, Mongenobacter, Haemophilus (Haemophilus influenzae and parainfluenzae), Pasteurella multocida, Yersinia, Campylobacter, and Gardnerella vaginalis. Chromosome-mediated beta-lactamase-producing and non-producing bacteria: Citrobacter freundii, isocitrogenic bacteria, Providencia, Morgenbacterium, Serratia (Serratia marcescens, Serratia hydraulica), Pseudomonas aeruginosa and other Pseudomonas (Pseudomonas cepacia, Pseudomonas fluorescens, Pseudomonas maltophilia), Acinetobacter. Gram-positive bacteria: beta-lactamase-producing and non-producing bacteria: Streptococcus (Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus bovis, Streptococcus agalactiae, Streptococcus viridans, Group C and Group G Streptococci), Enterococcus (Enterococcus faecalis, Enterococcus faecium), Staphylococcus aureus (excluding MRSA), Staphylococcus saprophyticus, Staphylococcus epidermidis (coagulase-negative staphylococci), Corynebacterium, Listeria monocytogenes, Nocardia. Anaerobic bacteria: the following bacteria that produce and do not produce beta-lactamases: Bacteroides (Bacteroides dipathonis, Bacteroides dimorphus, Bacteroides polytrichoides, Bacteroides melaninogenicus, Bacteroides oralis), Bacteroides fragilis (Bacteroides fragilis, Bacteroides vulgaris, Bacteroides ovipositor, Bacteroides thetaiotaomicron, Bacteroides monothecae, Bacteroides insaccharolyticus), Peptostreptococcus, Clostridium (Clostridium difficile, Clostridium perfringens), Veillonella, and Actinomycetes.

This product is a compound preparation, its components are piperacillin sodium and tazobactam sodium.

This product is white powder or off-white loose mass or powder, odorless, bitter and highly hygroscopic.

This product is suitable for moderate and severe infections caused by β-lactamase-producing bacteria that are resistant to piperacillin but sensitive to piperacillin-tazobactam: 1. Appendicitis (accompanied by perforation or abscess) and peritonitis caused by piperacillin-resistant, β-lactamase-producing Escherichia coli and Bacteroides (Bacteroides fragilis, Bacteroides ovale, Bacteroides thetaiotaomicron or Bacteroides vulgaris). 2. Uncomplicated and complicated skin and soft tissue infections caused by piperacillin-resistant, β-lactamase-producing Staphylococcus aureus, including cellulitis, skin abscesses, ischemic or diabetic foot infections. 3. Postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, β-lactamase-producing Escherichia coli. 4. Community-acquired pneumonia caused by piperacillin-resistant, β-lactamase-producing Haemophilus influenzae.

After fully dissolving an appropriate amount of this product with 20 ml of diluent (sodium chloride injection or sterile water for injection), immediately add it to 250 ml of liquid (5% glucose injection or sodium chloride injection) and drip it intravenously for at least 30 minutes each time. The course of treatment is 7 to 10 days. The course of treatment for hospital-acquired pneumonia is 7 to 14 days. It can be adjusted according to the condition and bacteriological examination results. For adults with normal renal function (creatinine clearance 90 ml/min) and children over 12 years old, 3.375 g (containing piperacillin 3 g and tazobactam 0.375 g) is dripped intravenously once every 6 hours. When treating hospital-acquired pneumonia, the starting dose is 3.375 g once, once every 4 hours, and aminoglycosides are used in combination; if Pseudomonas aeruginosa is not isolated, aminoglycosides can be considered to be discontinued according to the degree of infection and condition. For patients with renal insufficiency, the recommended dosage is shown in the table below: Creatinine clearance (ml/min) recommended dosage 40-90: 3.375g once, once every 6 hours, total daily amount 12g/1.5g; 20-40: 2.25g once, once every 6 hours, total daily amount 8g/1.0g; <20: For hemodialysis patients, the maximum dose is 2.25g once, once every 8 hours, and an additional 0.75g can be added after each hemodialysis.

1 Common adverse reactions of this product include: (1) Skin reactions: rash, itching, etc. (2) Gastrointestinal reactions: such as diarrhea, nausea, vomiting, etc. (3) Allergic reactions. (4) Local reactions: such as local irritation reactions after injection, pain, phlebitis, thrombophlebitis and edema, etc. (5) Other reactions: such as thrombocytopenia, pancreatitis, fever, fever with eosinophilia, increased serum aminotransferase, etc.; these reactions occur when this product is combined with aminoglycoside drugs for treatment. 2 In addition, the following adverse reactions may also be seen with this product: (1) Diarrhea, constipation, nausea, vomiting, abdominal pain, indigestion, etc. (2) Maculopapular rash, herpes, urticaria, eczema, etc. (3) Irritability, dizziness, anxiety, etc. (4) Other reactions: such as rhinitis, dyspnea

It is contraindicated for patients who are allergic to penicillins, cephalosporins or beta-lactamase inhibitors.

1. This product has no synergistic effect with gentamicin against Enterococcus faecalis. It can also have synergistic effect with some cephalosporins against some sensitive strains of Escherichia coli, Pseudomonas aeruginosa, Klebsiella and Proteus. 2. In in vitro tests, this product can inactivate aminoglycosides when used in combination with aminoglycosides. When this product is used in combination with tobramycin, the area under the drug-time curve, renal clearance and urinary excretion of tobramycin will decrease by 11%, 32% and 38% respectively, because piperacillin-tazobactam may inactivate tobramycin. In patients with severe renal insufficiency, such as hemodialysis patients, the pharmacokinetics of tobramycin will change when it is combined with piperacillin. 3. This product can prolong the half-life of piperacillin by 21% and the half-life of tazobactam by 71% when used in combination with probenecid. 4. Piperacillin, like carbenicillin, azlocillin, mezlocillin, and ticarcillin, may increase the risk of coagulation disorders and bleeding when used in combination with drugs that can cause hypoprothrombinemia, thrombocytopenia, gastrointestinal ulcers, or bleeding. Such as anticoagulants: heparin, coumarin, indandione; nonsteroidal anti-inflammatory analgesics, especially aspirin, diflunisal and other salicylic acid preparations, other platelet aggregation inhibitors or sulfinpyrazone. 5. This product cannot be mixed with other drugs in a syringe or infusion bottle. When used with other antibiotics, they must be administered separately. It must not be mixed with solutions containing only sodium bicarbonate, and blood products and hydrolyzed protein solutions must not be added.

Protect from light, seal tightly, and store in a dry and cool place.

4.5g (C23H27N5O7S4.0g and C10H12N4O5S0.5g)

Shanghai SPH New ASIA Pharmaceutical Co., Ltd.

• Founded in:

  1993-08-11

• Address:

  No. 978 Chuansha Road, Pudong New Area, Shanghai

• Tax NO.:

  91310115133738906M

• Registered Funds:

  1,052,429,132 yuan

• Website:

  Log in to view

• Email:

  Log in to view